Cargando…

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study

INTRODUCTION: The safety, pharmacokinetics, and effect on peripheral and central amyloid β (Aβ) of multiple doses of ponezumab, an anti-Aβ monoclonal antibody, were characterized in subjects with mild-to-moderate Alzheimer's disease treated for 1 year. METHODS: Subjects were aged ≥50 years with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Landen, Jaren W., Andreasen, Niels, Cronenberger, Carol L., Schwartz, Pamela F., Börjesson-Hanson, Anne, Östlund, Henrik, Sattler, Catherine A., Binneman, Brendon, Bednar, Martin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651442/ https://www.ncbi.nlm.nih.gov/pubmed/29067345 http://dx.doi.org/10.1016/j.trci.2017.05.003

Ejemplares similares

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Immunotherapy with ponezumab for probable cerebral amyloid angiopathy
por: Leurent, Claire, et al.
Publicado: (2019)

Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease
por: Li, Yi, et al.
Publicado: (2008)

Identifying Mild Alzheimer's Disease With First 30-Min (11)C-PiB PET Scan
por: Shen, Chushu, et al.
Publicado: (2022)

Quantitative Analysis of PiB-PET with FreeSurfer ROIs
por: Su, Yi, et al.
Publicado: (2013)

Can (11)C-PiB-PET Relative Delivery R(1) or (11)C-PiB-PET Perfusion Replace (18)F-FDG-PET in the Assessment of Brain Neurodegeneration?
por: Oliveira, Francisco P.M., et al.
Publicado: (2018)

Diagnostic Value of (11)C-PIB PET/MR in Cardiac Amyloidosis
por: Bi, Xiao, et al.
Publicado: (2022)

Advances in diagnosing mild cognitive impairment and Alzheimer’s disease using (11)C-PIB- PET/CT and common neuropsychological tests
por: Zhao, Qing, et al.
Publicado: (2023)

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology
por: Laforce, Robert, et al.
Publicado: (2014)

Brain Network Alterations in Alzheimer's Disease Identified by Early-Phase PIB-PET
por: Fu, Liping, et al.
Publicado: (2018)

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
por: Su, Yi, et al.
Publicado: (2018)

Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition
por: Stephen, Ruth, et al.
Publicado: (2017)

Diagnostic Value of Muscle [(11)C] PIB-PET in Inclusion Body Myositis
por: Noto, Yu-ichi, et al.
Publicado: (2020)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

The correlation of neuropsychological evaluation with (11)C-PiB and (18)F-FC119S amyloid PET in mild cognitive impairment and Alzheimer disease
por: Park, Su Yeon, et al.
Publicado: (2020)

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil
por: Fullerton, Terence, et al.
Publicado: (2018)

Plasma Based Markers of [(11)C] PiB-PET Brain Amyloid Burden
por: Kiddle, Steven John, et al.
Publicado: (2012)

Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors
por: Johnson, Derek R., et al.
Publicado: (2017)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

(11)C-PIB PET imaging reveals that amyloid deposition in cases with early-onset Alzheimer’s disease in the absence of known mutations retains higher levels of PIB in the basal ganglia
por: Youn, Young Chul, et al.
Publicado: (2017)

Formation of Microfiltration Membranes from PMP/PIB Blends: Effect of PIB Molecular Weight on Membrane Properties
por: Ilyin, Sergey, et al.
Publicado: (2020)

MR-Less Surface-Based Amyloid Assessment Based on (11)C PiB PET
por: Zhou, Luping, et al.
Publicado: (2014)

Negative (11)C-PIB PET Predicts Lack of Alzheimer’s Disease Pathology in Postmortem Examination
por: Scheinin, Noora M., et al.
Publicado: (2018)

Noninvasive Measurement of [(11)C]PiB Distribution Volume Using Integrated PET/MRI
por: Okazawa, Hidehiko, et al.
Publicado: (2020)

Unidirectional Influx and Net Accumulation of PIB
por: Blomquist, Gunnar, et al.
Publicado: (2008)

Function and evolution of Magnaporthe oryzae avirulence gene AvrPib responding to the rice blast resistance gene Pib
por: Zhang, Shulin, et al.
Publicado: (2015)

Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease
por: Yan, Lirong, et al.
Publicado: (2017)

Added Diagnostic Value of (11)C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis
por: Frederiksen, K.S., et al.
Publicado: (2012)

FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice
por: Yousefi, Behrooz H, et al.
Publicado: (2015)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia
por: Gault, Laura M., et al.
Publicado: (2015)

Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort study
por: Henderson, Catherine, et al.
Publicado: (2019)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Enhanced EGFP Fluorescence Emission in Presence of PEG Aqueous Solutions and PIB(1000)-PEG(6000)-PIB(1000) Copolymer Vesicles
por: Muhammad, Noor, et al.
Publicado: (2013)

Evaluation of 10-minute post-injection (11)C-PiB PET and its correlation with (18)F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer’s disease
por: Carneiro, Camila de Godoi, et al.
Publicado: (2022)

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
por: Ikonomovic, Milos D., et al.
Publicado: (2008)

Quantification and accuracy of clinical [11C]-PiB PET/MRI: the effect of MR-based attenuation correction
por: Law, Ian, et al.
Publicado: (2014)

Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies
por: Peretti, Débora E., et al.
Publicado: (2019)

Diagnostic value of blood thiamine metabolites in Alzheimer’s disease examined by (11)C-PiB PET scanning
por: Chen, Zhichun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7lmvh195ls5ufgo7s09108nkq3